# Genotyping Market

> Genotyping Market Research Report Information By Technology (Sequencing, Capillary Electrophoresis, PCR, Others), By Product (Reagents and Kits, Instruments, Services), By Application (Diagnostics, Drug Discovery and Development, Academic Research, Research and Development Centers), By End Users (Hospitals, Diagnostic Centers, Academic Institutes, Research and Development Centers), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 22.22%
- **2024:** $ 2,419.96 Million
- **2025:** $ 2,957.68 Million
- **2035:** $ 21,997.96 Million
- **Key Players:** Thermo Fisher Scientific (US), Illumina (US), Roche (CH), Agilent Technologies (US), Qiagen (DE), Bio-Rad Laboratories (US), PerkinElmer (US), BGI Genomics (CN), Genomatix (DE)

**Report ID:** MRFR/LS/5172-HCR · **Pages:** 85 · **Author:** Rahul Gotadki & Kinjoll Dey · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/genotyping-market-6635

---

## Market Summary

## **Genotyping Market Overview**

As per MRFR analysis, the Genotyping Market Size was estimated at 2.42 (USD Billion) in 2024. The Genotyping Market Industry is expected to grow from 2.96 (USD Billion) in 2025 to 18.00 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 8.90%% during the forecast period (2025 - 2034). Due to the anticipated rise in genetic illness, technological advancements, a sharp increase in demand for tailored treatment, and rising research and development activities in the healthcare sector are the key market drivers enhancing the market growth.

Moreover, the lower prices of genotyping services also aid the growing market.

Source Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

In February 2024, Benchmark Holdings' genetics division, a corporation specializing in aquaculture biotechnology, has broadened its range of products and services by introducing cost-effective genotyping instruments and services. Benchmark Genetics has announced a new offering that allows for tissue sample-to-data genotyping at a cost of €14.50 (£12.41) per sample. This step greatly enhances the availability of advanced genomic tools in the worldwide business, positioning Benchmark as a full provider of genetic support services. This expansion is founded on the extensive expertise of Benchmark Genetics and the Akvaforsk Genetics Centre.

It is the result of years of designing and providing technical assistance for selection programs in over 20 aquaculture species globally. The company currently provides a comprehensive range of genetic enhancement services, including complex multi-trait programs and cost-effective, focused programs that can easily integrate into existing commercial agricultural operations. Benchmark's revised offering encompasses high-density arrays and genotyping services for a diverse variety of farmed aquaculture species, as well as medium-density solutions for other species. The solution takes advantage of Benchmark's extensive genotyping capabilities in its salmon and shrimp breeding programs.

Services include high-density array genotyping starting at €14.5 for multiple species.

In September 2023, Bio-Rad Laboratories, Inc., a prominent company in the field of life science research and clinical diagnostics, introduced the PTC Tempo 48/48 and PTC Tempo 384 Thermal Cyclers. These devices are specifically designed to facilitate PCR applications in various areas such as basic and translational research, process development, and quality control. The PTC Tempo 48/48 and PTC Tempo 384 Thermal Cyclers are the most recent models included in Bio-Rad's collection of traditional PCR thermal cyclers.

The PTC Tempo Thermal Cyclers have been designed with an updated and user-friendly interface, as well as versatile connectivity tools to simplify protocol management. These features include the ability to monitor and control the cyclers using the BR.io cloud platform. The PTC Tempo Thermal Cyclers are designed to consistently provide excellent thermal performance. These cyclers give scientists the ability to easily adjust and expand their experiments within the laboratory. The PTC Tempo 48/48 Thermal Cycler is equipped with two separate dual blocks and manual lids, enabling the concurrent execution of two independent protocols.

The PTC Tempo 384 Thermal Cycler is designed for laboratories that handle a large number of samples. It is equipped with a motorized top, allowing for automation compatibility and interface with robotics.

## **Genotyping Market Trends**

### **Growing Prevalence of spine degeneration to boost the market growth**

The  genotyping market is majorly driving the demand for genotypic-based diagnostic testing in healthcare facilities worldwide. Various attributes affect the genotyping market, such as the increased Prevalence of chronic diseases, cancer, and genetic disorders. Along with this, the rising adoption of bioinformatics solutions in pharmacogenomics and data analysis in the discovery of drug and development processes is also a stimulus for market growth. With the significant rise in the investments in research and development work solely focusing on research of precision medicine and development of the genomic drug.

Other than the above factors, there is a positive outlook on the  market growth due to the ever-increasing demands for reagents for the augmenting volumes of tests related to genotyping.

Apart from this, the factors that are contributing to the  genotyping market revenue growth include the rising elderly population, as they are more susceptible to developing numerous medical conditions, the rise in awareness related to personalized medicines among the common people, continual technological development in the genotyping products and significant expansion of the healthcare expenditures.

## **Genotyping Market Segment Insights**

### **Genotyping Technology Insights**

Based on technology, the genotyping market segmentation includes Sequencing, Capillary Electrophoresis, [Polymerase Chain Reaction](../../../reports/polymerase-chain-reaction-market-19212) (PCR), and others. In 2022, the PCR segment controlled the market and had the biggest revenue share. This large market share may be attributed to the expanding need for sophisticated diagnostic methods, the rise of CROs, forensic and research laboratories and the rising Prevalence of diseases, including genetic disorders and chronic illnesses.

Sequencing's increased specificity and superior capacity to detect low expression & differentially expressed genes compared to other approaches are further reasons for its prediction to grow profitably during the projection period. Without a reference genome, a comparative examination of samples can be carried out with the aid of genotyping by sequencing.

### **Genotyping Product Insights**

Based on product, the genotyping market segmentation includes reagents and kits, instruments, and services. In 2022, the market for reagents and kits had the biggest share. Rising R&D expenditures, genotyping testing volumes, and genetic testing demand brings this on. Due to the increasing usage of software-based services by research laboratories and academic institutions, it is also projected that the software & services market will grow at a high rate. The effectiveness of sequencing techniques is increased by using bioinformatics, and errors made by conventional sequencing techniques are reduced.

Applications for these services can be found in agrigenomics, human diseases, animals, and microorganisms. All of the factors above are expected to drive market growth throughout the projection period.

****

**_Source Secondary Research, Primary Research, MRFR Database and Analyst Review_**

### **Genotyping Application Insights**

The genotyping market data has been bifurcated by application into drug discovery and development, academic research, and research and development centers. During the projected period, drug discovery and development are anticipated to increase at the quickest rate of any technology. Based on the patient's genetic makeup, genotyping assists in identifying individuals who are suited for a certain medicine. The attrition rate in clinical trials can be decreased by identifying population subsets that are responsive or non-responsive to provide these patients with individualized treatment. Key players also contribute actively by offering drug discovery and development research remedies.

For instance, TaqMan assays and QuantStudio tools are included in Thermo Fisher Scientific's RT PCR solution for pharmacogenomic testing. Together with a PharmacoScan Assay Kit, it also offers a PharmacoScan solution.

### **Genotyping End User Insights**

Based on End Users, the genotyping industry has been segmented into hospitals, diagnostic centers, academic institutes, and research and development centers. Due to the rising usage of genotyping products for research and the rising need for diagnosing genetic illnesses & cancer, the diagnostic center market is anticipated to grow at the fastest CAGR rate during the forecast period. The market is anticipated to be driven by the rising frequency of cancer and the rising demand for diagnostic tests such as cancer genotyping assays.

### **Genotyping Regional Insights**

By Region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. North America Genotyping market accounted for USD 3.0 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period, attributable to the rising use of technologically improved products, the existence of large pharmaceutical & biopharmaceutical businesses, proactive government actions, and developments in healthcare infrastructure. The presence of significant players in this Region is another key reason responsible for the high market share.

Further, the major countries studied in the market report are The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

****

**_Source Secondary Research, Primary Research, MRFR Database and Analyst Review_**

Europe genotyping market accounts for the second-largest market share due to several variables, including technical developments and the expanding pharma and biopharma business in the area, which can be blamed for the vast latent growth. Further, the Germany genotyping market held the largest market share, and the UK genotyping market was the fastest-growing market in the European Region.

The Asia-Pacific Genotyping Market is expected to grow at the fastest CAGR from 2022 to 2030. This is due to the increased number of clinical trials. Moreover, the China genotyping market held the largest market share, and the India genotyping market was the fastest-growing in Asia-Pacific.

**Genotyping Key Market Players & Competitive Insights**

Leading market players are investing a lot of money in R&D to expand their product portfolios, which will spur further growth for Genotyping industry. With significant industry changes like new product releases, contractual agreements, mergers and acquisitions, increased investments, market developments and collaboration with other organizations, market participants are also undertaking various strategic activities to expand their presence. Genotyping industry competitors must provide affordable products to grow and remain in a market that is becoming increasingly competitive.

Manufacturing locally to cut operational costs is one of the main business tactics used by genotyping manufacturers to serve customers and increase the market sector. The genotyping market major player such as QIAGEN, Affymetrix, Illumina, Thermo Fisher Scientific, and others are working on expanding the market demand by investing in research and development activities.

More than 140 nations are served by the American biotechnology corporation Illumina, Inc., headquartered in San Diego, California. Illumina, founded on April 1, 1998, creates, produces, and sells integrated systems for studying genetic variation and biological function. The business offers a selection of goods and services to cater to the markets for sequencing, genotyping and gene expression, and proteomics. Illumina and Roche worked together in January 2020 to increase patient access to oncology genomic testing.

Thermo Fisher Scientific Inc. Thermo Fisher, headquartered in Waltham, Massachusetts, is an American provider of scientific equipment, reagents, consumables, and software services. It was created in 2006 by the union of Thermo Electron and Fisher Scientific. Several reagent, consumable, instrument, and service suppliers have been purchased by Thermo Fisher Scientific, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021). Thermo Fisher Scientific increased its production capacity in August 2021. To diagnose the Delta and Lambda strains of SARS-CoV-2, the business updated its Applied Biosystems TaqMan SARS-CoV-2 mutation panel.

The panel allows labs to monitor known mutations by letting them choose from a list of more than 50 assays made to screen for various variants.

**Key Companies in the genotyping market include**

## Genotyping Market Industry Developments

- **Q2 2024: Illumina Launches NextSeq 2000Dx Sequencing System for Clinical Genotyping** Illumina announced the commercial launch of its NextSeq 2000Dx, a clinical-grade sequencing platform designed to expand genotyping capabilities for diagnostic laboratories, following CE-IVD marking.
- **Q2 2024: Thermo Fisher Scientific Expands Genotyping Portfolio with New Applied Biosystems QuantStudio 7 Pro Dx Real-Time PCR System** Thermo Fisher Scientific introduced the QuantStudio 7 Pro Dx Real-Time PCR System, targeting clinical laboratories for high-throughput genotyping applications and regulatory compliance.
- **Q2 2024: QIAGEN Acquires Verogen to Strengthen Genotyping Solutions for Forensics** QIAGEN completed the acquisition of Verogen, a leader in next-generation sequencing for forensic genotyping, aiming to expand its portfolio in human identification and genetic analysis.
- **Q3 2024: 23andMe Announces Strategic Partnership with AstraZeneca for Pharmacogenomic Genotyping** 23andMe entered a multi-year partnership with AstraZeneca to leverage its genotyping platform for pharmacogenomic research, focusing on drug response and personalized medicine.
- **Q3 2024: Genetron Health Receives FDA Clearance for Genotyping-Based Cancer Diagnostic Panel** Genetron Health secured FDA clearance for its new genotyping-based panel designed to detect actionable mutations in solid tumors, expanding its U.S. clinical diagnostics footprint.
- **Q3 2024: Bio-Rad Laboratories Opens New Genotyping Assay Manufacturing Facility in California** Bio-Rad Laboratories inaugurated a state-of-the-art facility dedicated to the production of genotyping assay kits, aiming to meet rising global demand for precision medicine tools.
- **Q4 2024: Pacific Biosciences Raises $150 Million in Public Offering to Accelerate Genotyping Technology Development** Pacific Biosciences completed a $150 million public offering, with proceeds earmarked for advancing its long-read genotyping platforms and expanding commercial operations.
- **Q4 2024: Agilent Technologies Appoints New VP of Genomics Division to Drive Genotyping Innovation** Agilent Technologies announced the appointment of Dr. Lisa Chen as Vice President of its Genomics Division, tasking her with leading genotyping product development and strategic partnerships.
- **Q1 2025: Thermo Fisher Scientific Wins Major Genotyping Contract with UK Biobank** Thermo Fisher Scientific secured a multi-year contract to supply genotyping platforms and reagents to UK Biobank, supporting large-scale population genomics research.
- **Q1 2025: Genomics Startup Helix Raises $80 Million Series C to Expand Genotyping Services** Helix, a U.S.-based genomics startup, closed an $80 million Series C funding round to scale its direct-to-consumer and clinical genotyping offerings.
- **Q2 2025: Roche Launches New High-Throughput Genotyping Platform for Clinical Labs** Roche introduced a high-throughput genotyping system designed for clinical laboratories, enabling faster and more accurate genetic variant detection for personalized medicine.
- **Q2 2025: Illumina and BGI Announce Collaboration to Develop Advanced Genotyping Solutions for Asia-Pacific Market** Illumina and BGI entered a strategic collaboration to co-develop genotyping technologies tailored for the Asia-Pacific region, focusing on population-scale genomics and clinical diagnostics.

## **Genotyping Market Segmentation**

### **Genotyping Technology Outlook**

### **Genotyping Product Outlook**

### **Genotyping Application Outlook**

### **Genotyping End User Outlook**

### **Genotyping Regional Outlook**

## Market Drivers

### Rising Demand for Personalized Medicine

The Global Genotyping Market Industry experiences a notable surge in demand for [personalized medicine](https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937), driven by advancements in genomic research. As healthcare shifts towards tailored treatments, genotyping plays a crucial role in identifying genetic variations that influence drug responses. This trend is exemplified by the increasing integration of genotyping in pharmacogenomics, which enhances therapeutic efficacy. The market is projected to reach 2.42 USD Billion in 2024, reflecting the growing recognition of personalized approaches in healthcare. By 2035, the market could expand to 19.6 USD Billion, indicating a robust CAGR of 20.95% from 2025 to 2035, as more healthcare providers adopt these technologies.

### Increasing Prevalence of Genetic Disorders

The Global Genotyping Market Industry is significantly influenced by the rising prevalence of genetic disorders, which necessitates efficient diagnostic tools. Conditions such as cystic fibrosis, sickle cell anemia, and various hereditary cancers underscore the importance of early detection and intervention. Genotyping Market provides critical insights into genetic predispositions, enabling healthcare professionals to implement preventive measures and personalized treatment plans. The growing awareness of genetic testing among patients and healthcare providers is likely to drive demand for genotyping services. As the global population ages and the incidence of genetic disorders rises, the market is poised for substantial growth.

### Growing Awareness and Adoption of Genetic Testing

The Global Genotyping Market Industry is witnessing a rise in awareness and adoption of genetic testing among consumers and healthcare providers. Educational campaigns and the proliferation of information regarding the benefits of genetic testing contribute to this trend. Patients are increasingly seeking genetic tests for various purposes, including ancestry tracing, disease risk assessment, and reproductive health. This heightened awareness is driving demand for genotyping services, as individuals recognize the potential for informed health decisions. As the market evolves, the integration of genetic testing into routine healthcare practices is anticipated to further stimulate growth, aligning with the projected market expansion.

### Technological Advancements in Genotyping Techniques

Technological innovations significantly impact the Global Genotyping Market Industry, enhancing the accuracy and efficiency of genotyping processes. The advent of next-generation sequencing (NGS) and CRISPR technologies has revolutionized genetic analysis, allowing for high-throughput and cost-effective genotyping. These advancements facilitate large-scale studies and clinical applications, driving market growth. For instance, NGS enables researchers to analyze entire genomes rapidly, which is essential for understanding complex diseases. As these technologies continue to evolve, they are expected to attract substantial investments, further propelling the market forward and contributing to the anticipated growth trajectory.

### Government Initiatives and Funding for Genomic Research

Government initiatives and funding play a pivotal role in shaping the Global Genotyping Market Industry. Numerous countries are investing in genomic research to enhance public health outcomes and foster innovation. For example, national genomic initiatives aim to sequence large populations to identify genetic variants associated with diseases. These programs not only facilitate research but also promote the development of new genotyping technologies. Increased funding from governmental bodies is expected to accelerate advancements in the field, thereby expanding the market. As public health policies increasingly prioritize genomic medicine, the market is likely to benefit from sustained governmental support.

## Future Outlook

The Genotyping Market is projected to grow at a 22.22% CAGR from 2025 to 2035, driven by advancements in technology, increasing demand for personalized medicine, and rising genetic research funding.

**New opportunities:**

- Development of portable genotyping devices for field research applications.
- Expansion of genotyping services in emerging markets to capture new customer segments.
- Integration of AI-driven analytics for enhanced data interpretation and decision-making.

By 2035, the Genotyping Market is expected to achieve substantial growth, solidifying its role in healthcare and research.

## Segment Insights

### By Application: Pharmacogenomics (Largest) vs. Forensic Analysis (Fastest-Growing)

In the Genotyping Market, the application segments are distinctly defined, with pharmacogenomics holding the largest share. This segment benefits from increasing adoption in personalized medicine, driving significant interest among healthcare providers and patients. Following closely, disease diagnosis plays a pivotal role, while agricultural genotyping and forensic analysis have carved out niche markets, appealing to specific sectors. The dynamic distribution highlights how these applications satisfy diverse needs, from healthcare to agriculture and public safety.

Recent growth trends indicate that the forensic analysis segment is emerging as the fastest-growing area within the genotyping market. Innovations in forensic technology and increasing crime rates are propelling this growth. In addition, pharmacogenomics remains robust due to rising investments in personalized therapies, while agricultural genotyping is witnessing gradual growth driven by advancements in crop science. These trends depict a multifaceted market landscape fueled by technological advancements and societal demands.

Pharmacogenomics (Dominant) vs. Forensic Analysis (Emerging)

Pharmacogenomics is recognized as the dominant application in the Genotyping Market due to its crucial role in tailoring drug therapies based on individual genetic profiles. This application significantly enhances treatment efficacy and minimizes adverse drug reactions, leading to better patient outcomes. It is widely adopted by healthcare systems globally. In contrast, forensic analysis is emerging rapidly owing to advancements in DNA testing technologies and an uptick in forensic investigations. This segment is characterized by its growing involvement in criminal justice and paternity testing, driven by the need for accurate and reliable identification solutions. As both segments evolve, their interplay is likely to shape future strategies in the Genotyping Market.

### By Technology: Next Generation Sequencing (Largest) vs. PCR (Fastest-Growing)

In the Genotyping Market, the distribution of market share among the technology segment showcases a robust presence of Next Generation Sequencing (NGS), which stands out as the largest segment. NGS has gained significant traction due to its ability to deliver high-throughput sequencing and comprehensive genomic insights. Meanwhile, Polymerase Chain Reaction (PCR) has positioned itself as the fastest-growing segment, driven by its established applications in research and clinical diagnostics, highlighting the diverse technology landscape within genotyping.

Technology: NGS (Dominant) vs. PCR (Emerging)

Next Generation Sequencing (NGS) dominates the Genotyping Market, favored for its advanced capabilities in high-volume sequencing and detailed analysis of genetic variations. This technology efficiently identifies mutations, facilitates personalized medicine, and supports large-scale genomic studies. While PCR continues to serve essential functions in various applications, its rapid growth is attributed to improvements in efficiency and sensitivity, making it increasingly relevant in diagnostic and research settings. The flexibility and adaptability of both technologies are key to their sustained relevance, with NGS leading the charge in innovation and application breadth.

### By End User: Pharmaceutical Companies (Largest) vs. Academic Research Institutions (Fastest-Growing)

In the genotyping market, the distribution of market share among end users is diverse, with pharmaceutical companies holding the largest share. These companies leverage genotyping for drug development and personalized medicine which enhances their operational efficacy. On the other hand, academic research institutions, while holding a smaller share, are rapidly increasing their footprint in this market as they engage in groundbreaking research harnessing advanced genotyping technologies to drive scientific discoveries and innovations.

Pharmaceutical Companies (Dominant) vs. Academic Research Institutions (Emerging)

Pharmaceutical companies have established themselves as the dominant end users in the genotyping market, utilizing advanced technologies to expedite drug discovery and development processes. They invest significantly in genotyping to align therapies with patient genotypes, ensuring better treatment outcomes. Conversely, academic research institutions are emerging players, increasingly turning to genotyping to facilitate extensive research projects aimed at understanding genetic variations and their implications in health and disease. This growth is fueled by collaborations with biotech firms and increasing funding for genetic research, positioning them as key contributors to the advancement of genotyping methodologies.

## Regional Market Share Analysis

### North America : Market Leader in Genotyping

North America continues to lead the genotyping market, holding a significant share of 1210.0M in 2024. The region's growth is driven by advancements in biotechnology, increasing demand for personalized medicine, and supportive regulatory frameworks. The presence of major players like Thermo Fisher Scientific and Illumina further fuels market expansion, as they innovate and enhance product offerings to meet rising consumer needs. The United States is the primary contributor to this market, supported by a robust healthcare infrastructure and substantial investments in research and development. Canada also plays a vital role, with increasing collaborations between academic institutions and industry leaders. The competitive landscape is characterized by strategic partnerships and mergers, ensuring that North America remains at the forefront of genotyping technologies.

### Europe : Emerging Market with Growth Potential

Europe's genotyping market is poised for growth, with a market size of 800.0M in 2024. The region benefits from a strong emphasis on research and development, particularly in genomics and personalized medicine. Regulatory support from bodies like the European Medicines Agency (EMA) encourages innovation and ensures compliance, driving demand for advanced genotyping solutions across various sectors, including healthcare and agriculture. Leading countries such as Germany, the UK, and France are at the forefront of this market, hosting numerous key players like Qiagen and Roche. The competitive landscape is marked by collaborations between biotech firms and academic institutions, fostering innovation. As Europe continues to invest in genomic research, the market is expected to expand, providing opportunities for both established and emerging companies.

### Asia-Pacific : Rapidly Growing Genotyping Sector

The Asia-Pacific region is witnessing a rapid expansion in the genotyping market, with a size of 350.0M in 2024. This growth is driven by increasing investments in healthcare infrastructure, rising awareness of genetic testing, and government initiatives promoting biotechnology. Countries like China and India are leading this trend, supported by favorable regulations and a growing population seeking personalized healthcare solutions. China stands out as a major player, with companies like BGI Genomics leading the charge in innovation and technology. India is also emerging as a significant market, with a focus on affordable genetic testing solutions. The competitive landscape is evolving, with both local and international players vying for market share, indicating a promising future for the genotyping sector in this region.

### Middle East and Africa : Untapped Market with Potential

The Middle East and Africa (MEA) region represents an untapped market for genotyping, with a size of 59.96M in 2024. The growth in this region is primarily driven by increasing healthcare investments and a rising demand for genetic testing. Governments are beginning to recognize the importance of genomics in healthcare, leading to supportive policies and initiatives aimed at enhancing biotechnology capabilities. Countries like South Africa and the UAE are emerging as key players in the genotyping landscape, with growing interest from both local and international companies. The competitive environment is characterized by collaborations and partnerships aimed at improving access to genetic testing services. As awareness of the benefits of genotyping increases, the MEA region is expected to see significant growth in the coming years.

## Competitive Benchmarking

The Genotyping Market is characterized by a dynamic competitive landscape, driven by advancements in technology, increasing demand for personalized medicine, and the growing prevalence of genetic disorders. Key players such as Thermo Fisher Scientific (US), Illumina (US), and Roche (CH) are at the forefront, each adopting distinct strategies to enhance their market positioning. Thermo Fisher Scientific (US) focuses on innovation through the development of advanced genotyping platforms, while Illumina (US) emphasizes partnerships to expand its product offerings and reach. Roche (CH) is strategically investing in digital transformation to streamline operations and improve customer engagement, collectively shaping a competitive environment that prioritizes technological advancement and customer-centric solutions.
In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and enhance supply chain efficiency. The Genotyping Market appears moderately fragmented, with a mix of established players and emerging companies. The collective influence of these key players is significant, as they drive innovation and set industry standards, thereby impacting market dynamics and competitive strategies.
In November 2025, Illumina (US) announced a strategic partnership with a leading biotechnology firm to co-develop next-generation sequencing technologies. This collaboration is expected to enhance Illumina's capabilities in precision medicine, allowing for more accurate and efficient genotyping solutions. The strategic importance of this partnership lies in its potential to accelerate product development and expand market reach, positioning Illumina as a leader in the rapidly evolving landscape of genomic technologies.
In October 2025, Roche (CH) launched a new genotyping assay that integrates artificial intelligence (AI) to improve data analysis and interpretation. This innovative approach not only enhances the accuracy of genotyping results but also streamlines workflows for laboratories. The introduction of AI into Roche's offerings signifies a critical shift towards integrating advanced technologies in genotyping, which could redefine operational efficiencies and customer satisfaction in the market.
In September 2025, Thermo Fisher Scientific (US) completed the acquisition of a smaller genomics company, thereby expanding its portfolio of genotyping solutions. This acquisition is strategically significant as it allows Thermo Fisher to leverage new technologies and expertise, enhancing its competitive edge in the market. The move reflects a broader trend of consolidation within the industry, as companies seek to strengthen their positions through strategic acquisitions and broaden their technological capabilities.
As of December 2025, the Genotyping Market is witnessing trends such as digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve, with a shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition underscores the importance of agility and responsiveness in meeting the demands of a rapidly changing market.

## Recent News & Developments

- **Q2 2024: Illumina Launches NextSeq 2000Dx Sequencing System for Clinical Genotyping Market** Illumina announced the commercial launch of its NextSeq 2000Dx, a clinical-grade sequencing platform designed to expand genotyping capabilities for diagnostic laboratories, following CE-IVD marking.
- **Q2 2024: Thermo Fisher Scientific Expands Genotyping Market Portfolio with New Applied Biosystems QuantStudio 7 Pro Dx Real-Time PCR System** Thermo Fisher Scientific introduced the QuantStudio 7 Pro Dx Real-Time PCR System, targeting clinical laboratories for high-throughput genotyping applications and regulatory compliance.
- **Q2 2024: QIAGEN Acquires Verogen to Strengthen Genotyping Market Solutions for Forensics** QIAGEN completed the acquisition of Verogen, a leader in next-generation sequencing for forensic genotyping, aiming to expand its portfolio in human identification and genetic analysis.
- **Q3 2024: 23andMe Announces Strategic Partnership with AstraZeneca for Pharmacogenomic Genotyping Market** 23andMe entered a multi-year partnership with AstraZeneca to leverage its genotyping platform for pharmacogenomic research, focusing on drug response and personalized medicine.
- **Q3 2024: Genetron Health Receives FDA Clearance for Genotyping Market-Based Cancer Diagnostic Panel** Genetron Health secured FDA clearance for its new genotyping-based panel designed to detect actionable mutations in solid tumors, expanding its U.S. clinical diagnostics footprint.
- **Q3 2024: Bio-Rad Laboratories Opens New Genotyping Market Assay Manufacturing Facility in California** Bio-Rad Laboratories inaugurated a state-of-the-art facility dedicated to the production of genotyping assay kits, aiming to meet rising global demand for precision medicine tools.
- **Q4 2024: Pacific Biosciences Raises $150 Million in Public Offering to Accelerate Genotyping Market Technology Development** Pacific Biosciences completed a $150 million public offering, with proceeds earmarked for advancing its long-read genotyping platforms and expanding commercial operations.
- **Q4 2024: Agilent Technologies Appoints New VP of Genomics Division to Drive Genotyping Market Innovation** Agilent Technologies announced the appointment of Dr. Lisa Chen as Vice President of its Genomics Division, tasking her with leading genotyping product development and strategic partnerships.
- **Q1 2025: Thermo Fisher Scientific Wins Major Genotyping Market Contract with UK Biobank** Thermo Fisher Scientific secured a multi-year contract to supply genotyping platforms and reagents to UK Biobank, supporting large-scale population genomics research.
- **Q1 2025: Genomics Startup Helix Raises $80 Million Series C to Expand Genotyping Market Services** Helix, a U.S.-based genomics startup, closed an $80 million Series C funding round to scale its direct-to-consumer and clinical genotyping offerings.
- **Q2 2025: Roche Launches New High-Throughput Genotyping Market Platform for Clinical Labs** Roche introduced a high-throughput genotyping system designed for clinical laboratories, enabling faster and more accurate genetic variant detection for personalized medicine.
- **Q2 2025: Illumina and BGI Announce Collaboration to Develop Advanced Genotyping Market Solutions for Asia-Pacific Market** Illumina and BGI entered a strategic collaboration to co-develop genotyping technologies tailored for the Asia-Pacific region, focusing on population-scale genomics and clinical diagnostics.

## Report Scope

| MARKET SIZE 2024 | 2419.96(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 2957.68(USD Million) |
| MARKET SIZE 2035 | 21997.96(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 22.22% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Thermo Fisher Scientific (US), Illumina (US), Roche (CH), Agilent Technologies (US), Qiagen (DE), Bio-Rad Laboratories (US), PerkinElmer (US), BGI Genomics (CN), Genomatix (DE) |
| Segments Covered | Application, Technology, End Use |
| Key Market Opportunities | Advancements in personalized medicine drive demand for innovative solutions in the Genotyping Market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation and competition in the genotyping market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Genotyping Market as of 2024?**
A: The Genotyping Market was valued at approximately 2419.96 USD Million in 2024.

**Q: What is the projected market size for the Genotyping Market in 2035?**
A: The Genotyping Market is projected to reach approximately 21997.96 USD Million by 2035.

**Q: What is the expected CAGR for the Genotyping Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Genotyping Market during the forecast period 2025 - 2035 is 22.22%.

**Q: Which application segment had the highest valuation in 2024?**
A: The Disease Diagnosis application segment had the highest valuation at approximately 1210.0 USD Million in 2024.

**Q: How does the Agricultural Genotyping segment perform in terms of market valuation?**
A: The Agricultural Genotyping segment was valued at approximately 484.0 USD Million in 2024.

**Q: What are the leading technologies in the Genotyping Market?**
A: The leading technologies include Next Generation Sequencing, valued at approximately 800.0 USD Million in 2024.

**Q: Which end user segment contributed the most to the Genotyping Market in 2024?**
A: The Clinical Laboratories segment contributed the most, with a valuation of approximately 845.96 USD Million in 2024.

**Q: Who are the key players in the Genotyping Market?**
A: Key players in the Genotyping Market include Thermo Fisher Scientific, Illumina, Roche, and Qiagen.

**Q: What is the market valuation for SNP Genotyping technology in 2024?**
A: The SNP Genotyping technology was valued at approximately 519.96 USD Million in 2024.

**Q: What is the projected growth trend for the Genotyping Market by 2035?**
A: The Genotyping Market is expected to experience substantial growth, reaching approximately 21997.96 USD Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/genotyping-market-6635*